EISAI AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS OF THE FINAL ANALYSIS FOR BAN2401 AT 18 MONTHS
July 6, 2018
Eisai Co., Ltd.
Biogen Inc.●The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain
●First late-stage study data successfully demonstrating potential disease-modifying effects on both clinical function and amyloid beta accumulation in the brain
●New data provide compelling evidence to further support amyloid hypothesis as a therapeutic target for Alzheimer’s disease
https://www.eisai.com/news/2018/news201858.html
Biogen is skyrocketing after its Alzheimer’s drug delivers positive results (BIIB) | Markets Insider
An Alzheimer’s drug thought to be a failure may work after all – Quartz
https://www.bloomberg.co.jp/news/articles/2018-07-06/PBFWTU6KLVTU01
Alzheimer’s research gets glimmer of hope, but not for first time | The Japan Times